

COVID-19 Therapeutics

Melissa Solis, MD, CDPH




COVID-19 Therapeutics Key Points

COVID-19 treatments can help prevent severe illness in eligible* patients

CDPH recommends that providers prescribe:

- ✓ Nirmatrelvir/ritonavir (Paxlovid) to non-hospitalized, symptomatic, and eligible patients
- ✓ Remdesivir (Veklury) should be considered when nirmatrelvir/ritonavir (Paxlovid) is clinically contraindicated
- ✓ Molnupiravir (Lagevrio) may be considered if remdesivir is impractical and Paxlovid is clinically contraindicated.



*Eligibility depends on exposure status, symptoms, and [risk factors](#) for severe disease

PEMGARDA (pemivibart): Emergency Use Authorization (EUA)

PEMGARDA has **not** been approved

PEMGARDA is **not** authorized for:

- × Treatment of COVID-19, or
- × Post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with COVID-19



-
- **EUA authorization** for the **pre-exposure prophylaxis (PrEP)** of COVID-19 in certain adults and adolescent individuals:

✓ Who are not currently infected with covid-19 and who have not had a known recent exposure to an individual with COVID-19

-AND-


✓ Who are moderately-to-severely immunocompromised and are unlikely to mount an adequate response to COVID-19 vaccination

PEMGARDA (pemivibart) EUA Update

Limitations of Authorized Use

Pemgarda is authorized for use only when:

The combined national frequencies of variants with substantially reduced susceptibility to Pemgarda is less than or equal to 90% based on available information including variant susceptibility to Pemgarda and national variant frequencies.




CDC COVID Data Tracker: Variant Proportions

Weighted and Nowcast Estimates in United States for 2-Week Periods in 5/26/2024 – 9/14/2024

Nowcast Estimates in United States for 9/1/2024 – 9/14/2024

Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate.



USA			
WHO label	Lineage #	% Total	95%PI
Omicron	KP.3.1.1	52.7%	48.6-56.8%
	KP.2.3	12.2%	10.8-13.8%
	LB.1	10.9%	9.4-12.6%
	KP.3	10.6%	9.3-12.1%
	KP.2	3.1%	2.2-4.2%
	LP.1	2.1%	1.4-3.0%
	KP.1.1.3	1.9%	1.4-2.8%
	JN.1.18	1.7%	0.6-4.0%
	KP.1.1	1.5%	1.2-1.9%
	KS.1	0.7%	0.4-1.0%
	KP.2.15	0.7%	0.4-1.0%
	LF.3.1	0.6%	0.4-0.9%
	JN.1.16.1	0.6%	0.4-0.8%
	KP.4.1	0.2%	0.1-0.4%
	JN.1.11.1	0.2%	0.1-0.3%
	JN.1	0.2%	0.1-0.3%
	KW.1.1	0.0%	0.0-0.1%
	XDV.1	0.0%	0.0-0.1%
	JN.1.16	0.0%	0.0-0.0%
	JN.1.7	0.0%	0.0-0.0%
	KP.1.2	0.0%	0.0-0.0%
	KQ.1	0.0%	0.0-0.0%
	JN.1.8.1	0.0%	0.0-0.0%
	JN.1.32	0.0%	0.0-0.0%

** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates
 # Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one 2-week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all 2-week periods displayed
 While all lineages are tracked by CDC, those named lineages not enumerated in this graphic are aggregated with their parent lineages, based on Pango lineage definitions, described in more detail here: <https://web.archive.org/web/20240116214031/https://www.pango.network/the-pango-nomenclature-system/statement-of-nomenclature-rules>.


[EUA Invivyd Pemgarda LOA \(PDF\)](#)

[HCP Fact Sheet \(PDF\)](#)

PEMGARDA (pemivibart)

Limitations of Authorized Use Continued

Have a weakened immune system?



COVID-19 vaccines

Pemgarda

Talk to your healthcare provider about preventing COVID-19 with Pemgarda and COVID-19 vaccines

- PrEP with Pemgarda is **not** a substitute for vaccination and all individuals who can receive vaccination should do so.
 - Individuals should wait to receive Pemgarda until at least 2 weeks after COVID-19 vaccination.

PEMGARDA (pemivibart): How to Obtain and Prescribe

- PEMGARDA may only be prescribed by physicians, advanced practice registered nurses, and physician assistants who are licensed or authorized under State law.
- [Pemgarda Ordering Guide](#) (PDF)
- If you need further information, please contact the INVIVYD Medical Information Department at 1-800-890-3385 or emailmedinfo@invivyd.com.



PEMGARDA is currently available to order in the United States from the following specialty distributors.

PEMGARDA NDC/UPC: 81960-031-03

Cardinal Health	
Phone	855.855.0708
Email	gmb-spd-csorderentry@cardinalhealth.com
Portal	Specialty Online: specialtyonline.cardinalhealth.com Order Express: orderexpress.cardinalhealth.com
Account Setup	866.677.4844
McKesson Plasma and Biologics	
Phone	877.625.2566
Email	mpborders@mckesson.com
Portal	https://connect.mckesson.com/
Account Setup	mpbonboarding@mckesson.com
McKesson Specialty Care Distribution	
Phone	800.482.6700
Email	physvcscustcare@mckesson.com
Portal	https://mscs.mckesson.com/
Account Setup	onboarding2@mckesson.com

Image: Pemgarda: Package Insert - Drugs.com

CDPH Webpages Updated

The screenshot shows the CDPH website header with the logo and navigation links: "I am looking for", "I am a", "Programs", and "A-Z Index". Below the header is a blue banner for "COVID-19 Treatments". The main content area features a sidebar with a list of links including "Division of Communicable Disease Control Homepage", "California Reportable Disease Information Exchange (CalREDIE)", "Communicable Disease Emergency Response Program", "Immunization Branch", "Infectious Diseases Branch", "Office of Viral Hepatitis Prevention", "Sexually Transmitted Diseases Control Branch", "Tuberculosis Control Branch", "COVID-19", "COVID-19 Wastewater Surveillance", and "DCDC Contact Us". The main content area has a sub-header "Getting Treatments" with a paragraph of text. Below this is a section titled "COVID-19 Treatment Resources" with two columns: "For the General Public" (with a colorful balloon image) and "For Healthcare Providers and Facilities" (with a stethoscope image).

The screenshot shows the CDPH website header with the logo and navigation links: "I am looking for", "I am a", "Programs", and "A-Z Index". Below the header is a blue banner for "COVID-19 Vaccines". The main content area features a sidebar with a list of links including "COVID-19 Home", "Protect Your Health", "Get Latest Guidance", "See the Numbers", and "Learn More". The main content area has a sub-header "Stay Up to Date on COVID-19 Vaccines" with a paragraph of text. Below this is a section titled "Updated 2024-2025 COVID-19 vaccines (Pfizer, Moderna, and Novavax) are available now!" with a paragraph of text. Below the text is a blue button labeled "Staying up to date with COVID-19 Vaccines" and a white button labeled "COVID-19 Vaccine FAQ". The background image shows a family of four smiling.

The screenshot shows the CDPH website header with the logo and navigation links: "I am looking for", "I am a", "Programs", and "A-Z Index". Below the header is a blue banner for "COVID-19 Testing". The main content area features a sidebar with a list of links including "COVID-19 Home", "Protect Your Health", "Get Latest Guidance", "See the Numbers", and "Learn More". The main content area has a sub-header "How & When to Test for COVID-19" with a paragraph of text. Below the text is a blue button labeled "Find a Testing Site" and a white button labeled "What to Know About Testing". The background image shows a man lying in bed being attended to by a healthcare worker.

[COVID-19 Treatments](#)

[COVID-19 Vaccines](#)

[COVID-19 Testing](#)

Treatments: A core strategy to prevent progression to severe disease



Antiviral treatments are available for persons with mild to moderate COVID-19

These treatments can reduce the risk of severe COVID-19 and other complications

Studies show that **high risk** adults (older age, in **LTCFs/SNFs**, unvaccinated, with comorbidities) **are not getting treated!**

Remember:

- Treatments are effective against circulating variants.
- Antiviral treatments are largely safe for elderly individuals.
- Check for contraindications (most meds can be held)
 - <https://www.covid19-druginteractions.org/>
- Creatinine is relevant for patients with known kidney disease (e.g. renal dosing) but otherwise, not required.



[Treatment Options for COVID-19 | HHS/ASPR](#)